Table 4.
Incidence and adjusted risk of ESKD in patients stratified in subgroups by the combination of hyperkalaemia and RASI categories over the two study visits.
| Hyperkalaemia | RASI | Incidence (events/pts) | Incidence Rate (per 100-pts-y) | sHR (95% CI) | p |
|---|---|---|---|---|---|
| Absent/Resolving | Yes | 137/1.018 | 3.18 (2.67–3.75) | Reference | - |
| Absent/Resolving | No | 144/518 | 9.02 (7.61–10.62) | 1.09 (0.83–1.44) | 0.540 |
| New onset/Persistent | Yes | 171/632 | 7.43 (6.36–8.63) | 1.18 (0.94–1.49) | 0.140 |
| New onset/Persistent | No | 115/275 | 16.55 (13.67–19.87) | 1.57 (1.20–2.06) | 0.001 |
Hyperkalaemia defined by sK ≥ 5.0 mEq/L over the two study visits. sHR, sub-hazard ratio; CI, confidence interval; RASI, inhibitors of renin-angiotensin system. Yes, RASI prescription at both visits or only visit 2; No, RASI prescription at only visit 1 or at none of the two visits. The model is stratified by cohort and adjusted for variables at visit 2 (age, gender, diabetes, CV disease, BMI, haemoglobin, eGFR, 24 h proteinuria, systolic BP) as for eGFR change between the two study visit.